Skip to main content

Table 2 Predictive factors for DAS28(ESR) <2.6 at week 12 identified by univariate and multivariate logistic regression analysis

From: Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study

  Univariate analysis Multivariate analysis
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Age 0.99 (0.95–1.02) 0.41   
RA duration 1.00 (0.99–1.00) 0.37   
MTX dose 1.07 (0.94–1.238) 0.30   
DAS28(ESR) 0.50 (0.31–0.75) <0.001 0.67 (0.40–1.06) 0.09
HAQ-DI 0.69 (0.36–1.29) 0.25   
EQ-5D 41.89 (1.88–1496.64) 0.02 1.66 (0.01–287.19) 0.83
CRP 0.88 (0.73–1.03) 0.12   
RF 1.00 (0.99–1.00) 0.50   
ACPA 1.00 (0.99–1.00) 0.30   
MMP-3 1.00 (0.99–1.00) 0.69   
TNFα 1.18 (0.98–1.72) 0.09   
IL-6 1.00 (0.99–1.01) 0.46   
HAQ-DI at 24 h 0.53 (0.25–1.04) 0.07   
EQ-5D at 24 h 123.61 (4.82–5356.39) <0.001 26.33 (0.514–7838.05) 0.09
CRP at 24 h 0.85 (0.66–1.02) 0.08   
CRP at 48 h 0.77 (0.53–1.02) 0.07   
TNFα at 24 h 0.20 (0.05–0.55) <0.001 0.01 (0.04e−2–0.22) <0.01
TNFα at 48 h 0.01 (2.636e-5–0.54) <0.001 9.26 (0.30–342.47) 0.20
IL-6 at 24 h 0.98 (0.95–0.99) 0.03 1.00 (0.97–1.01) 0.92
IL-6 at 48 h 0.04 (0.01–0.60) 0.02 0.97 (0.92–1.03) 0.27
CZP at 24 h 15.56 (1.95–154.84) <0.001 1.00 (0.99–1.01) 0.33
CZP at 48 h 16.76 (1.82–190.40) 0.01 1.00 (0.99–1.01) 0.24
  1. RA rheumatoid arthritis, MTX methotrexate, DAS disease activity score, HAQ-DI health assessment questionnaire disability index, EQ-5D EuroQol 5 Dimension, CRP C-reactive protein, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibody, MMP-3 matrix metalloproteinase 3, TNFα tumor necrosis factor, IL-6 interleukin-6, CZP cerolizumab pegol